ReviewCurrent opinion in molecular therapeutics2008
Challenges to the translation of genomic information into clinical practice and health policy: Utilization, preferences and economic value.
Review in Current opinion in molecular therapeutics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Do economic evaluations of targeted therapy provide support for decision makers?The American journal of managed care · 2011Pooled it
- Operationalizing Precision Medicine in Drug Development: Predictive Biomarkers, Companion Diagnostics, and Regulatory Pathways.Clinical pharmacology and therapeutics · 2026Review
- Review
- Identification of potential key genes and functional role of CENPF in osteosarcoma using bioinformatics and experimental analysis.Experimental and therapeutic medicine · 2022Article
- Women's preferences for cancer risk management strategies in Lynch syndrome.Gynecologic oncology · 2019Article
- Assessing patient readiness for personalized genomic medicine.Journal of community genetics · 2019Article
- The economic value of personalized medicine tests: what we know and what we need to know.Genetics in medicine : official journal of the American College of Medical Genetics · 2014Article
- Oncologists' attitudes toward KRAS testing: a multisite study.Cancer medicine · 2013Article
- Issues surrounding the health economic evaluation of genomic technologies.Pharmacogenomics · 2013Review
- Closing the personalized medicine information gap: HER2 test documentation practice.The American journal of managed care · 2013Article
- Utilization of HER2 genetic testing in a multi-institutional observational study.The American journal of managed care · 2012Article
- HER2 evaluation and its impact on breast cancer treatment decisions.Public health genomics · 2012Article
- Tradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer.Medical care · 2011Article
- Do economic evaluations of targeted therapy provide support for decision makers?Journal of oncology practice · 2011Article
- Personalized medicine and comparative effectiveness research in an era of fixed budgets.The EPMA journal · 2010Article
- Capacity building for assessing new technologies: approaches to examining personalized medicine in practice.Personalized medicine · 2010Article
- Paving the Way to Personalized Genomic Medicine: Steps to Successful Implementation.Current pharmacogenomics and personalized medicine · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
It is important to understand how knowledge of genomics can be translated from research into clinical practice and health policies. This review examines existing evidence on three key factors in the adoption of personalized medicine: utilization, preferences, and economic value, using two cancer examples: HER2/neu antigen testing and trastuzumab (Herceptin) treatment and genetic testing for Lynch syndrome. Our findings highlight areas in which additional research is required to build an evidence base addressing utilization of, preferences for, and the potential costs and benefits of personalized medicine. Major challenges include a lack of linked data, the need for relevant research frameworks and methodologies, and the clinical complexities of genomic-based diagnostics and treatment.
Indexed as
Identifiers
18535933PMC2910510What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.